The goal of this protocol is to isolate endothelial progenitor cells from umbilical cord blood. Some of the applications include using these cells as a biomarker for identifying patients with cardiovascular risk, treating ischemic diseases, and creating tissue-engineered vascular and heart valve constructs.
The existence of endothelial progenitor cells (EPCs) in peripheral blood and its involvement in vasculogenesis was first reported by Ashara and colleagues1. Later, others documented the existence of similar types of EPCs originating from bone marrow2,3. More recently, Yoder and Ingram showed that EPCs derived from umbilical cord blood had a higher proliferative potential compared to ones isolated from adult peripheral blood4,5,6. Apart from being involved in postnatal vasculogenesis, EPCs have also shown promise as a cell source for creating tissue-engineered vascular and heart valve constructs7,8. Various isolation protocols exist, some of which involve the cell sorting of mononuclear cells (MNCs) derived from the sources mentioned earlier with the help of endothelial and hematopoietic markers, or culturing these MNCs with specialized endothelial growth medium, or a combination of these techniques9. Here, we present a protocol for the isolation and culture of EPCs using specialized endothelial medium supplemented with growth factors, without the use of immunosorting, followed by the characterization of the isolated cells using Western blotting and immunostaining.
Several investigators have studied the characteristics and potential of human EPCs5,10,11,12,13. EPCs can be described as circulating cells that have the ability to adhere to endothelial tissue in sites of hypoxia, ischemia, injury, or tumor formation and contribute to the formation of new vascular structures4,14. Their observed involvement in neovascularization, in the form of postnatal vasculogenesis, has led to an understanding of the pathophysiology of these cells and their use in therapeutic applications4,15,16. The number of EPCs in an individual has been shown to be correlated with cardiovascular pathology9,15,16,17,18,19,20. Other studies have also differentiated EPCs into a valve fibroblast-like phenotype and proposed that these cells could be used for tissue-engineering heart valves7,21.
The particular cell surface molecules needed to isolate EPCs have not been clearly identified due to discrepancies between investigations4. The adhesion of MNCs to a certain matrix, with exposure to a variety of culture conditions, has been performed by several groups1,17,22,23, suggesting that putative EPCs may display different phenotypic properties. These properties include a lack of phagocytotic ability, tube formation in Matrigel, and the uptake of Dil-acetylated low-density lipoproteins. The high clonogenic and proliferative potential are two properties with which EPCs can be hierarchized5. EPCs can also form in vitro tubules when cocultured with human fetal lung fibroblasts4. These cells are known to express endothelial cell surface markers and to share some of the hematopoietic markers13,24,25. The positively expressed markers that are widely accepted for phenotyping EPCs are CD31, CD34, vascular endothelial growth factor receptor 2 (VEGFR2), von Willebrand Factor (vWF), CD133, c-Kit, and vascular endothelial cadherin (VE-cadherin)4,18. Cells that co-express CD90, CD45, CD14, CD115, or alpha-smooth muscle actin (α-SMA) are not considered to be EPCs because of their limited proliferative potential, ability to phagocytose bacteria, and inability to form de novo human vessels in vivo4,7. This article outlines a modified protocol for the isolation of endothelial progenitor cells from human umbilical cord blood without the need for any cell sorting protocols. For this article, we used CD31, CD34, and VEGFR2 as the positive markers, with α-SMA as the negative indicator.
In this article, we propose a method of isolating and culturing endothelial progenitor cells from umbilical cord blood without cell sorting using specialized endothelial growth medium supplemented with growth factors (EGM). This EGM contains vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), which enhance the survival, proliferation, and migration of endothelial cells26. It also includes ascorbic acid, which is responsible for maintaining the cobblestone morphology of cells; insulin-like growth factor-1 (IGF-1), which provides angiogenic and migratory function; and heparin, which causes improved long-term stability of growth factors in the medium26. Other growth factors added to the endothelial cell culture medium includes supplementation with epidermal growth factor (EGF), which helps in stimulating cell proliferation and differentiation, and hydrocortisone, which sensitizes the cells to EGF26. We show that the use of this specific growth medium yields higher numbers of EPCs compared to endothelial basal medium (EBM) or Dulbecco's Modified Eagle Medium (DMEM).
This research was carried out with the approval of the University of Arkansas Institutional Review Board (Approval number 16-04-722). Umbilical cord blood units were collected in citrate phosphate dextrose (CPD) solution at the Arkansas Cord Blood Bank, and units that did not meet the requirement for storage were donated for research. Cord blood units were couriered to the lab within 24 h of collection at ambient temperatures.
1. Isolation of Endothelial Progenitor Cells from Cord Blood
2. Characterization of Isolated Cells Using Western Blotting
3. Indirect Immunofluorescence
Isolation and Expansion of Endothelial Progenitor Cells:
A schematic (Figure 1) is provided depicting the overall protocol. The different blood component layers were observed following density gradient centrifugation of human umbilical cord blood with density gradient medium. Upon seeding MNCs onto the collagen-treated plates, the outgrowth of colonies was first observed between Days 5 and 7 (Figure 2A). These colonies continued to grow and had a spindle-shaped cell morphology (Figure 2A-2D) in the early stages, which later progressed to a cobblestone-like morphology (Figure 2E-2F). Figure 3A shows the total number of cells versus time in culture, and each data point represents the cumulative number of cells harvested at each passage. Figure 3B depicts the average time taken for the first colony to arise in the collagen-treated 6-well plate after seeding the MNCs.
Characterization Using Western Blotting:
Figure 4A shows the representative results of the Western blot membrane that was tested against the various antibodies. Our results suggest that the cells were positive for CD31 and CD34. The expression of CD31 (Figure 4B) and CD34 (Figure 4C) appeared to decrease over subsequent passages, whereas VEGFR2 (Figure 4D) was expressed equally in later passages, with the first passage having higher expression. We also observed that the EPCs did not express the mesenchymal cell marker α-SMA (Figure 4E). Human umbilical vein endothelial cells (HUVEC) and valvular interstitial cells (VIC) cell lysates were used as positive and negative controls, respectively. HUVECs are known to express CD31, CD34, and VEGFR2, while VICs express α-SMA.
Figure 1: Schematic of EPC Isolation. Start the isolation by diluting cord blood with HBSS and layering it carefully on top of the density gradient medium, as shown. Density gradient centrifugation of the layered blood is carried out to obtain distinct layers of the blood, which is comprised of MNCs (buffy coat), density gradient medium, granulocytes, and RBCs. The subset image provided shows these different layers. MNCs are collected and reseeded onto a collagen-treated cell culture plate. Please click here to view a larger version of this figure.
Figure 2. Progression of the Cell Colony. (A-E) Representative bright-field images of EPC colony progression over time. Note that the colony has spindle-shaped cells at the early stages, adopting the cobblestone morphology. (E) Representative image of EPC cultured in a T-75 flask at passage 3. Scale bar = 200 µm. Please click here to view a larger version of this figure.
Figure 3: Growth Curves of EPCs. (A) The graph depicts the number of cells growing over a period of time, and each of the data point denotes the cell number harvested during each passage (P0 – P10) (n = 4). (B) Time taken for the first EPC colony to appear in the 6-well plate (n = 4). The error bars denote the standard error of the mean (SEM). No statistical significance was found using one-way ANOVA. Please click here to view a larger version of this figure.
Figure 4: Western Blotting. (A) Western blot membrane stained with various antibodies. HUVEC lysate and VIC lysate were used as positive controls. (B) Average intensity of CD31 bands normalized with α-tubulin. (C) Average intensity of CD34 bands normalized with α-tubulin. (D) Average intensity of VEGFR2 bands normalized with α-tubulin. (E) Average intensity of α-SMA bands normalized with α-tubulin (n = 3 – 6). The error bars denote the SEM. No statistical significance was found using one-way ANOVA. Please click here to view a larger version of this figure.
Figure 5: Immunostaining. Representative images of EPCs cultured in EGM for 7 days and immunostained at various passages for CD31, CD34, VEGFR2, and α-SMA. Scale bar – 100 µm. Please click here to view a larger version of this figure.
Supplemental Figure 1: The graph depicts the number of cells per unit area over a period of 7 days when cultured in EGM, EBM, and DMEM. EGM showed higher cell growth compared with the media (EBM and DMEM). The data showed statistical significance, with p <0.01, using one-way ANOVA (n = 2). Please click here to view a larger version of this figure.
Supplemental Figure 2: Representative images of EPCs cultured in EBM for 7 days and immunostained for CD31, CD34, VEGFR2, and α-SMA. Scale bar = 100 µm. Please click here to view a larger version of this figure.
Supplemental Figure 3: Representative images of EPCs cultured in DMEM for 7 days and immunostained for CD31, CD34, VEGFR2, and α-SMA. Scale bar = 100 µm. Please click here to view a larger version of this figure.
As mentioned earlier, adherent EPCs possess a cobblestone morphology. Our isolated MNCs progressed from a spindle-shaped cell colony (Figure 2A-2D) in the early stages to a cobblestone colony (Figure 2E-2F) over a period of ten days in culture. EPCs have been labeled differently by different research groups, namely as late endothelial progenitor cells10, endothelial colony forming cells5, or endothelial progenitor cells12. It should be noted that these cells are functionally the same and express similar cell surface markers. The number of cells observed during the culture period (Figure 3) increased to almost 108 cells, analogous to previous publications and typical of the high proliferative potential of EPCs3,5. Indeed, it was found that EPCs obtained from human umbilical cord blood showed a high proliferative potential and demonstrated several population doublings before undergoing senescence compared to EPCs isolated from adult human peripheral blood5,10.
Our Western blotting results (Figure 4A) showed the presence of CD31, CD34, and VEGFR2 on the cell lysates obtained from EPCs compared to the positive control, HUVEC. HUVECs express CD31, CD34, and VEGFR2 and activated VIC express α-sSMA. Similar to previous reports10,18, the expression of CD31 decreased with higher passages. The expression pattern was also similar in the case of CD34 and VEGFR2, where both the markers were expressed strongly in the first passage and in relatively lower but equal amounts in later passages. This data shows a trend that is in agreement with previous groups' results, in which immunosorting-based protocols were used for isolating cord blood-derived EPCs12. Generally, EPCs do not express mesenchymal markers and, to verify that the isolated cells were not mesenchymal in nature, we immunolabeled our Western blot membranes with α-SMA. Our results clearly show that there was no α-SMA expression in the cultured EPCs when compared with positive control cell lysates collected from VICs, which exhibit strong expression of α-SMA antibody.
To demonstrate that EGM allows for increased cell proliferation compared to other culture media used for EPCs, we cultured the cells in three different types of media: DMEM, EBM, and EGM (i.e., EBM supplemented with growth factors, as outlined earlier). All were supplemented with 10% FBS. We seeded cells of different passages in each well of a 12-well plate. Supplemental Figure 1 shows the number of cells per unit area in each well over time in culture in the different media formulations. We note that the EPCs cultured in EGM showed a steady increase in cell number, and for cells in EBM, there was a slower rate of increase in cell number during the first three days, which subsequently plateaued. This suggests that the EPCs could still survive in EBM, but the absence of growth factors hindered proliferation. We also note that EPCs cultured in DMEM decline in number, suggesting that this particular medium formulation is not suitable for their survival or proliferation. Our immunostaining data shows that the EPCs cultured in EGM (Figure 5) expressed CD31 more when compared to EPCs cultured in EBM (Supplemental Figure 2) and DMEM (Supplemental Figure 3). Comparing Figure 5 with Supplemental Figure 2 and Supplemental Figure 3, it can be seen that the cells were not contaminated with other cell types. Also, when comparing the immunostained EPCs (Figure 5), we can qualitatively state that the expression of CD31 and CD34 decreased over higher passages, supporting our Western blot data (Figure 4).
To reiterate, the primary goal of our proposed protocol is to demonstrate that one can isolate endothelial progenitor cells by culturing blood MNCs in specialized selective media. This is to show that EPCs can be isolated without sophisticated equipment and procedures, unlike other methods that involve the use of flow cytometry – either immediately after MNC isolation1,3,20,30 or after the colonies have grown into a monolayer – followed by replating4,10,12,13,23. The EPC colonies usually appear between days 5 and 9. Our method is thus a faster and more cost-efficient method for isolating EPCs. The primary limitation of this technique is that the expression of CD31 and CD34 decreases with subsequent passages, which could suggest that the cells are losing their progenitor phenotype. Thus, it is recommended that one should use cells obtained from passage 5 or lower to conduct experiments if using this protocol.
Precautions should be taken after the density centrifugation to not disturb the different layers when taking the centrifuged tubes back into the hood and also when removing the plasma. Another critical step pertains to erythrocyte lysis, where a longer incubation time could potentially damage the MNC. It is thus recommended not to repeat this step more than twice. Indeed, since the medium aspiration is carried out 24 h after plating, trace amounts of erythrocytes are removed, as they are non-adherent. Alternative substrates, like fibronectin or gelatin, while not tested by us, can also be used according to the specific protocols for creating cell culture coatings. By employing minor modification in the initial steps, researchers may isolate non-adherent EPCs30.
In conclusion, we have reported a method of isolating EPCs from umbilical cord blood. It is important to note that the EPCs do not express markers like α-SMA, suggesting that they are not mesenchymal-like cells. Indeed, α-SMA serves as an important marker when trying to study the endothelial-mesenchymal transition (endo-MT) of EPCs. Endo-MT is a cellular transdifferentiation process during which endothelial cells are known to lose their specific markers and to transform to a mesenchymal-like cell phenotype. It has been shown that EPCs can undergo this transition in the presence of transforming growth factor-β7 and can release extracellular membrane proteins on their tissue-engineered scaffolds8. All these observations indicate the promise of EPCs for use as an autologous cell source to create a heart valve or other cardiovascular tissue-engineered constructs.
The authors have nothing to disclose.
This material is based upon work supported by the National Science Foundation under Grant No. CMMI-1452943 and by the University of Arkansas Honors College. We would also like to acknowledge the Arkansas Cord Blood Bank for providing us with cord blood units.
A) For isolation and culturing | |||
EGM-2 BulletKit | Lonza | CC-3162 | This product comes with all the growth factors needed to make the Endothelial Growth Medium |
Fetal Bovine Serum | Thermofisher Scientific | 26140079 | |
Pencillin-Streptomycin-Glutamine (100X) | Thermofisher Scientific | 10378016 | |
Ficoll-Paque | GE Heatlhcare | 17-1440-02 | |
Hank's Balanced Salt Solution | Thermofisher Scientific | 14170-112 | |
Ammonium Chloride | Stem Cell Technologies | 7850 | |
1X Phosphate Buffer Saline | Thermofisher Scientific | 14190250 | |
Rat Tail I Collagen | Corning | 354236 | |
Glacial Acetic Acid | Amresco | 0714-500ML | |
0.05% Trypsin-EDTA | Thermofisher Scientific | 25300054 | |
HEPES buffer | Thermofisher Scientific | 15630080 | |
Dulbecco's Modified Eagle's Medium | Thermofisher Scientific | 10566-016 | |
B) Antibodies and cell lysates | |||
CD31 | Abcam | ab28364 | 1:250 dilution for Western blotting |
CD34 | Santa Cruz Biotechnology | sc-7045 | 1:100 dilution for Western blotting |
α-SMA | abcam | ab5694 | 1:100 dilution for Western blotting |
α-tubulin | abcam | ab7291 | 1:2500 dilution for Western blotting |
VEGFR2 | abcam | sc504 | 1:100 dilution for Western blotting |
Human umbilical vein endothelial cell lysate | Santa Cruz Biotechnology | sc24709 | |
Valve interstitial cell lysate | Primary cell line cultured from own lab and lysed with RIPA buffer | ||
C) Western blotting and immunostaining | |||
10X Tris/Glycine/SDS buffer | Biorad | 161-0772 | Used as running buffer |
10X Tris/Glycine buffer | Biorad | 161-0771 | Used as transfer buffer |
Immobilon-FL transfer membrane | Merck Millipore | IPFL0010 | This is a PVDF transfer membrane that has 45 µm pore size and is mentioned in the protocol as western blot membrane |
4X Laemmli sample buffer | Biorad | 161-0747 | |
2-mercaptoethanol | Biorad | 161-0710 | |
10% Criterion TGX precast gel | Biorad | 5671033 | |
Prolong Gold antifade | Thermofisher Scientific | P36930 | Used for mounting immunostained coverslips for long term storage |
Methanol | VWR Analytical | BDH1135-4LP |